Onlypunjab.com News

Approval Within 24 Hours

Search:

Ezine Ready Article:

HTML Version:

<html>

<head><title>Erimos Pharmaceuticals Names Dr. Scott Mohrland as President and Chief Executive Officer</title>

</head>

Erimos Pharmaceuticals Names Dr. Scott Mohrland as President and Chief Executive Officer by <a href=http://www.share.citynewslive.com/profile/Health-News/2>Health News</a> Erimos Pharmaceuticals, a growing biopharmaceutical company focused primarily on the discovery, development and commercialization of small molecule therapeutics to treat cancer, today named its new President and CEO: J. Scott Mohrland, Ph.D. 
 
Dr. Mohrland is a pharmaceutical executive with more than 26 years of experience in the global pharmaceutical industry. His leadership has built and managed global organizations focused on the development and commercialization of oncology and other therapeutic products. 
 
Jeff Khoo, former Erimos CEO, will serve as Executive Vice Chairman on Erimos’ board of directors, and will continue to provide leadership at the board level to Erimos’ international expansion efforts. “Scott Mohrland has a gift for translating science into medical and commercial significance, which is especially valuable to a technology with this breadth of potential. His proven track record in global drug development and commercialization will advance both our lead oncology product and our many other product initiatives,” said Mr. Khoo. “We are very excited to have Scott at the helm during this important growth period for Erimos.” 
 
“It will be a real privilege and pleasure to work with Scott Mohrland again,” said Daniel D. Von Hoff, M.D., Special Advisor to the President and Clinical Advisor to Erimos, and an internationally recognized leader in cancer drug development. “Dr. Mohrland is science-driven with enormous expertise in anti-cancer drug development. His prior experience will provide a terrific compliment to the outstanding Erimos team.” 
 
Before joining Erimos, Dr. Mohrland served as Executive Vice President for GMP Companies, Inc., a global medical technology company focused on the development and commercialization of pharmaceuticals, medical devices and diagnostics. Prior to GMP, he spent more than 21 years with Pharmacia Corporation, Pharmacia and Upjohn, Inc. and the Upjohn Company, where he held a number of executive positions, including Vice President of Scientific, Professional and Government Operations, and Vice President of Medical Operations and Scientific Affairs. Dr. Mohrland has also served on several boards, including serving as Vice Chairman of Florida’s biotechnology industry organization, BioFlorida. He has held several academic appointments, including Adjunct Professor of Clinical Medicine at Western Michigan University. Dr. Mohrland, who also holds a bachelor’s degree in chemistry, received his PhD in pharmacology from Washington State University, and was a Postdoctoral Fellow at the University of Iowa, College of Medicine. He has authored numerous scientific and medical publications and been a member of several scientific and medical societies. 
 
Dr. Ru Chih Huang, Chief Scientific Advisor to Erimos, a biology professor at The Johns Hopkins University, and lead inventor of Erimos’ technology, said, “As Erimos expands clinical research internationally to tackle global and regional diseases with unmet need, Scott’s broad experience in clinical operations, drug development and business expansion will be invaluable in facilitating strong business relations in Asia, and later, throughout the world.” 
 
Erimos has exclusively licensed a portfolio of proprietary small molecules from The Johns Hopkins University and is developing a novel class of drugs including its lead candidate, terameprocol (EM-1421), which is designed specifically to target abnormal/tumor cells while causing little or no toxicity to healthy cells. Working at the DNA level, terameprocol is designed to prevent the production and activation of survivin, a protein that is produced excessively in tumor cells, thus preventing cell replication and enhancing the body’s ability to eliminate abnormal cells through cell death, or apoptosis. 
 
“This is an exciting time to join Erimos Pharmaceuticals as President and CEO. I look forward to leading the company’s efforts to provide novel pharmacotherapies for the treatment of cancer and other proliferating diseases. Erimos’ mechanistic approach has the potential to greatly impact the way we treat these diseases and significantly improve the quality of life for patients,” said Dr. Mohrland. 
 
Erimos’ lead product candidate, terameprocol is in Phase I/II clinical studies evaluating its use as an intravenous therapy for the treatment of refractory and metastatic solid tumors that are unresponsive to conventional therapy. Erimos recently commenced a Phase I study in partnership with the New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium to determine the maximum tolerated dose of terameprocol in adults with recurrent high grade glioma. An additional study, exploring terameprocol’s potential use in the treatment of hematological malignancies is scheduled to begin enrollment in the second quarter of 2007. Erimos completed a phase II pilot study evaluating terameprocol for the treatment of Cervical Intraepithelial Neoplasia (CIN), widely recognized as the precursor to cervical cancer, which demonstrated encouraging results for this indication. Additional pre-clinical programs are underway to evaluate new compounds to treat cancer and serious viral infections, including influenza.

For more information visit <A href="http://www.erimos.com" target=_blank 
shape=rect>www.erimos.com</A>.

Article Source: <a href="http://www.share.citynewslive.com">Onlypunjab.com News</a>

</body>

</html>

Text Version:

Erimos Pharmaceuticals Names Dr. Scott Mohrland as President and Chief Executive Officer by Health News

Erimos Pharmaceuticals, a growing biopharmaceutical company focused primarily on the discovery, development and commercialization of small molecule therapeutics to treat cancer, today named its new President and CEO: J. Scott Mohrland, Ph.D.

Dr. Mohrland is a pharmaceutical executive with more than 26 years of experience in the global pharmaceutical industry. His leadership has built and managed global organizations focused on the development and commercialization of oncology and other therapeutic products.

Jeff Khoo, former Erimos CEO, will serve as Executive Vice Chairman on Erimos’ board of directors, and will continue to provide leadership at the board level to Erimos’ international expansion efforts. “Scott Mohrland has a gift for translating science into medical and commercial significance, which is especially valuable to a technology with this breadth of potential. His proven track record in global drug development and commercialization will advance both our lead oncology product and our many other product initiatives,” said Mr. Khoo. “We are very excited to have Scott at the helm during this important growth period for Erimos.”

“It will be a real privilege and pleasure to work with Scott Mohrland again,” said Daniel D. Von Hoff, M.D., Special Advisor to the President and Clinical Advisor to Erimos, and an internationally recognized leader in cancer drug development. “Dr. Mohrland is science-driven with enormous expertise in anti-cancer drug development. His prior experience will provide a terrific compliment to the outstanding Erimos team.”

Before joining Erimos, Dr. Mohrland served as Executive Vice President for GMP Companies, Inc., a global medical technology company focused on the development and commercialization of pharmaceuticals, medical devices and diagnostics. Prior to GMP, he spent more than 21 years with Pharmacia Corporation, Pharmacia and Upjohn, Inc. and the Upjohn Company, where he held a number of executive positions, including Vice President of Scientific, Professional and Government Operations, and Vice President of Medical Operations and Scientific Affairs. Dr. Mohrland has also served on several boards, including serving as Vice Chairman of Florida’s biotechnology industry organization, BioFlorida. He has held several academic appointments, including Adjunct Professor of Clinical Medicine at Western Michigan University. Dr. Mohrland, who also holds a bachelor’s degree in chemistry, received his PhD in pharmacology from Washington State University, and was a Postdoctoral Fellow at the University of Iowa, College of Medicine. He has authored numerous scientific and medical publications and been a member of several scientific and medical societies.

Dr. Ru Chih Huang, Chief Scientific Advisor to Erimos, a biology professor at The Johns Hopkins University, and lead inventor of Erimos’ technology, said, “As Erimos expands clinical research internationally to tackle global and regional diseases with unmet need, Scott’s broad experience in clinical operations, drug development and business expansion will be invaluable in facilitating strong business relations in Asia, and later, throughout the world.”

Erimos has exclusively licensed a portfolio of proprietary small molecules from The Johns Hopkins University and is developing a novel class of drugs including its lead candidate, terameprocol (EM-1421), which is designed specifically to target abnormal/tumor cells while causing little or no toxicity to healthy cells. Working at the DNA level, terameprocol is designed to prevent the production and activation of survivin, a protein that is produced excessively in tumor cells, thus preventing cell replication and enhancing the body’s ability to eliminate abnormal cells through cell death, or apoptosis.

“This is an exciting time to join Erimos Pharmaceuticals as President and CEO. I look forward to leading the company’s efforts to provide novel pharmacotherapies for the treatment of cancer and other proliferating diseases. Erimos’ mechanistic approach has the potential to greatly impact the way we treat these diseases and significantly improve the quality of life for patients,” said Dr. Mohrland.

Erimos’ lead product candidate, terameprocol is in Phase I/II clinical studies evaluating its use as an intravenous therapy for the treatment of refractory and metastatic solid tumors that are unresponsive to conventional therapy. Erimos recently commenced a Phase I study in partnership with the New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium to determine the maximum tolerated dose of terameprocol in adults with recurrent high grade glioma. An additional study, exploring terameprocol’s potential use in the treatment of hematological malignancies is scheduled to begin enrollment in the second quarter of 2007. Erimos completed a phase II pilot study evaluating terameprocol for the treatment of Cervical Intraepithelial Neoplasia (CIN), widely recognized as the precursor to cervical cancer, which demonstrated encouraging results for this indication. Additional pre-clinical programs are underway to evaluate new compounds to treat cancer and serious viral infections, including influenza.

For more information visit www.erimos.com.

Article Source: http://www.share.citynewslive.com

Article Summary:

Keywords:

Article Url:

Free Content
Free content from users at Onlypunjab.com
Our Traffic Rankings

	Print This Article
	Post Comment
	Add To Favorites
	Email to Friends
	Ezine Ready

Submit Articles
Member Login
Top Authors
Most Popular Articles
Submission Guidelines
Ezine Notifications
Article RSS Feeds

New Stuff
About Us
Site Blog
Forum
Link to Us
Contact Us
Privacy Policy
Terms of Service

Arts and Entertainment
Astrology
Casino-Gambling
Humanities
Humor
Language
Movies
Music
Philosophy
Photography
Poetry
Tattoos
Automotive
Mobile-Audio-Video
Motorcycles
Trucks
Business
Advertising
Branding
Careers-Employment
Change-Management
Customer-Service
Entrepreneurialism
Ethics
Management
Marketing
Marketing-Direct
Negotiation
Networking
Outsourcing
PR
Presentation
Resumes-Cover-Letters
Sales
Sales-Management
Sales-Teleselling
Sales-Training
Small-Business
Strategic-Planning
Team-Building
Top7-or-10-Tips
Workplace and Communication
Cancer
Breast-Cancer
Colon-Rectal-Cancer
Leukemia-Lymphoma-Cancer
Lung-Mesothelioma-Asbestos
Ovarian-Cervical-Uterine-Cancer
Prostate-Cancer
Skin-Cancer
Communications
Computer
Certification-Tests
Data Recovery
Games
Hardware
Mobile-Computing
Personal Technology
Software
PHP
Web
html
Family
Babies-Toddler
Crafts-Hobbies
Elder Care
Holidays
Home Appliances
Home Audio/Video
Home Improvement
Home Security
Interior Decorating
Kids
Landscaping-Gardening
Parental Care
Pets
Pregnancy
Bankruptcy
Credit
Currency Trading
Debt Consolidation
Debt-Relief
Estate Plan Trusts
Insurance
Investments
Loans
Mortgages
Mutual Funds
Personal Finance
Real Estate
Real Estate FSBO
Structured Settlements
Taxes
Wealth Building
Food and Drink
Chocolate
Coffee
Cooking-Tips
Recipes
Wine-Spirits
Health
Acne
Aerobics Cardio
Alternative
Anti Aging
Beauty
Build Muscle
Depression
Diabetes
Exercise
Fitness Equipments
Hair Loss
Medicine
Meditation
Mens Issues
No Smoking
Nutrition
Obesity
Polution
Sidha
Supplements
Weight Loss
Womens Issues
Yoga
Home Based Business
Network-Marketing
Internet and Businesses Online
Affiliate-Revenue
Auctions
Audio-Streaming
Autoresponders
Blogging
Domain-Names
E-Books
Ecommerce
Email-Marketing
Ezine-Publishing
Forums
Internet-Marketing
List-Building
Podcasting
RSS
Security
Spam-Blocker
Video-Streaming
Web-Design
Web-Development
Web-Hosting
Kids and Teens
Legal
Identity-Theft
Living-Will
News and Society
Dating
Divorce
Economics
Love
Marriage-Wedding
Politics
Relationships
Religion
Sexuality
Reference and Education
College University
Education
Future Concepts
Home-Schooling
Science
Self Improvement
Addictions
Anger-Management
Attraction
Coaching
Creativity
Goal-Setting
Grief-Loss
Happiness
Innovation
Inspirational
Leadership
Motivation
Organizing
Positive-Attitude
Spirituality
Stress-Management
Success
Time-Management
Shopping and Product Reviews
Book-Reviews
Fashion-Style
Jewelry-Diamonds
Sport
Baseball
Cycling
Fishing
Football
Golf
Martial Arts
Running
Soccer
Swimming
Triathlon
Technology
Broad band
GPS
Mobile
Statellite
Video Conferencing
VOIP
Travel and Leisure
Aviation
Cruising-Sailing
Outdoors
Vacation-Rentals
Website Promotion
PPC-Advertising
SEO
Site-Promotion
Traffic-Building
Womens Interests
Writing and Speaking
Book-Marketing
Copywriting
Public-Speaking
Teleseminars
Writing
Writing-Articles